8-K: Senseonics Secures $25 Million Private Placement from Abbott Laboratories Alongside Public Offering

Senseonics Holdings, Inc. has entered into a securities purchase agreement with Abbott Laboratories for a private placement of up to $25 million of its common stock, contingent upon a proposed public offering.

Summary

• Senseonics Holdings, Inc. has agreed to a securities purchase agreement with Abbott Laboratories on May 15, 2025.
• Abbott will purchase up to $25 million of Senseonics' common stock in a private placement.
• The number of shares purchased will result in Abbott's beneficial ownership of 4.99% of Senseonics' common stock after the private placement and a proposed public offering.
• The purchase price will match the public offering price per share.
• The private placement is conditional on the closing of the proposed public offering and other customary conditions.
• Senseonics expects the private placement to close within two business days following the public offering's closing.
• Abbott will have certain information rights regarding the clinical and regulatory development status of Senseonics' Gemini and Freedom products, excluding competitively sensitive information.
• Abbott will have an exclusive negotiation period for strategic transactions like a merger or asset sale, expiring on the earliest of FDA clearance of the Freedom Product as an integrated continuous glucose monitor (iCGM) plus 90 days, December 31, 2032, or when Abbott owns less than 80% of the purchased shares.
• Senseonics terminated its equity distribution agreement with Goldman Sachs & Co. LLC in connection with the proposed public offering.
• The company updated its corporate presentation slide deck on May 15, 2025.

Sentiment

Score: 7

Explanation: The announcement is moderately positive. The private placement from Abbott is a strong vote of confidence in Senseonics' technology and future prospects. However, the contingency on the public offering and the risks associated with product development and commercialization temper the overall sentiment.

Positives

• The private placement provides Senseonics with a significant capital infusion of up to $25 million.
• Abbott's investment validates Senseonics' technology and market potential.
• The exclusive negotiation period for strategic transactions could lead to a beneficial partnership or acquisition.
• The information rights granted to Abbott could provide valuable insights and feedback on Senseonics' product development.

Negatives

• The private placement is contingent on the successful closing of the proposed public offering.
• The exclusive negotiation period does not obligate Senseonics to enter into any transaction.
• The information rights granted to Abbott exclude competitively sensitive information, potentially limiting the scope of the information shared.

Risks

• Uncertainties related to market conditions could impact the completion of the private placement and public offering.
• Failure to obtain FDA clearance for the Freedom Product could shorten the exclusive negotiation period with Abbott.
• The company's reliance on Ascensia Diabetes Care for commercialization efforts carries inherent risks.
• The development of the Gemini and Freedom systems are subject to change based on various factors.

Future Outlook

Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change and disclaims any obligation to update these forward-looking statements except as required by law.

Industry Context

The CGM market is rapidly growing, and Senseonics is positioning itself to capture a larger share with its long-term implantable technology. The partnership with Abbott and the development of new products like Gemini and Freedom are aimed at addressing unmet needs in the diabetes management space.

Comparison to Industry Standards

• Senseonics' Eversense CGM system competes with established players like Dexcom and Abbott (FreeStyle Libre) in the continuous glucose monitoring market.
• Eversense differentiates itself with its long-term implantable sensor, lasting up to 365 days, compared to the 10-15 day wear time of traditional CGMs.
• The accuracy of Eversense, with a MARD of 8.8% for the Eversense 365 sensor, is comparable to other leading CGM systems.
• The partnership with Sequel Med Tech to integrate with the twiist pump positions Senseonics to compete in the automated insulin delivery (AID) market, similar to Dexcom's integration with Tandem Diabetes Care's Control-IQ system.

Stakeholder Impact

• Shareholders will benefit from the capital infusion and potential for increased stock value.
• Employees will have increased job security and opportunities for growth.
• Customers will have access to innovative CGM technology.
• Suppliers will benefit from increased demand for Senseonics' products.
• Creditors will have increased confidence in Senseonics' financial stability.

Next Steps

• Senseonics will proceed with the proposed public offering.
• Senseonics will work to close the private placement with Abbott Laboratories following the public offering.
• Senseonics will continue the development of its Gemini and Freedom products.
• Senseonics will work with Ascensia Diabetes Care to expand the commercial reach of Eversense 365.
• Senseonics will integrate with Sequel Med Tech's twiist pump.

Key Dates

Keywords

Senseonics, Abbott Laboratories, Private Placement, Public Offering, Continuous Glucose Monitoring, CGM, Gemini, Freedom, Securities Purchase Agreement